Usefulness of insulin detemir in Japanese children with type 1 diabetes

• Published in: Pediatrics international Vol. 54; no. 6; pp. 773 - 779
• Main Authors: Jinno, Kazuhiko, Urakami, Tatsuhiko, Horikawa, Reiko, Kawamura, Tomoyuki, Kikuchi, Nobuyuki, Kikuchi, Tohru, Kizu, Rika, Kosaka, Kitaro, Mizuno, Haruo, Mochizuki, Takahiro, Nishii, Aki, Ohki, Yukashi, Soneda, Shun, Sugihara, Shigetaka, Tatematsu, Toshi, Amemiya, Shin
• Format: Journal Article
• Language: English
• Published: Melbourne, Australia Blackwell Publishing Asia 01.12.2012; Blackwell Publishing Ltd
• Subjects: Adolescent; basal insulin; blood glucose; Blood Glucose - metabolism; Child; Clinical outcomes; Diabetes; Diabetes Mellitus, Type 1 - blood; Diabetes Mellitus, Type 1 - drug therapy; Diabetes Mellitus, Type 1 - epidemiology; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug therapy; Female; Follow-Up Studies; Humans; hypoglycemia; Hypoglycemic Agents - administration & dosage; Injections, Subcutaneous; Insulin; Insulin Detemir; Insulin, Long-Acting - administration & dosage; Japan - epidemiology; Male; Morbidity - trends; Pediatrics; Retrospective Studies; Treatment Outcome; type 1 diabetes mellitus; Japan
• ISSN: 1328-8067; 1442-200X
• DOI: 10.1111/j.1442-200X.2012.03687.x

Background:  This multicenter observational study was conducted to investigate the efficacy and safety of insulin detemir (detemir) for diabetes management in Japanese children and adolescents. Methods:  Data from the Japanese Study Group of Insulin Therapy for Childhood and Adolescent Diabetes database were analyzed. Ninety children (32 boys, 58 girls; mean age, 11.9 ± 3.8 years) who transferred from a neutral protamine Hagedorn insulin or insulin glargine basal‐bolus regimen to detemir basal‐bolus therapy and who were observed for at least 12 months were identified. Clinical data obtained at 0, 3, 6, and 12 months were analyzed to determine the type of bolus insulin used, number and timing of detemir injections, detemir dose as a proportion of the total insulin dose, hemoglobin A1c (HbA1c), fasting blood glucose (FBG) and frequency of severe hypoglycemia. Results:  Twelve months after switching to detemir, the detemir dose represented 39.8% of the total insulin dose, and 37.8% of patients were being treated with twice‐daily injections. HbA1c and FBG were significantly reduced from baseline at 3 and 6 months but not at 12 months. Considering the seasonal HbA1c variation in the Japanese population, a separate analysis was performed using data for 65 children (21 boys, 44 girls; mean age, 11.6 ± 2.9 years) who switched to detemir during the winter. Subset analysis showed significant HbA1c reductions from baseline at all specified times. The incidence of severe hypoglycemia during detemir treatment was 4.4 episodes per 100 patient‐years. Conclusions:  Detemir is an effective and safe basal insulin for diabetes management in Japanese children and adolescents.